Bristows advises Syncona and Oxford Science Enterprises on $60m financing for Oyster Therapeutics
17.11.2026
Bristows has advised Syncona and Oxford Science Enterprises (OSE) on their participation in a $60 million Series A-2 financing for Oyster Therapeutics, a pharmaceutical company developing next-generation targeted protein degraders, with an initial focus on tau-driven diseases including Alzheimer’s.
The financing will support Oyster’s progress towards clinical development and the continued development of its pipeline of potential treatments for neurodegenerative diseases.
The round was led by 4BIO Capital, alongside participation from new and existing investors. Oyster, previously known as Kesmalea Therapeutics, also announced its rebrand alongside the financing as it enters its next phase of development.
The Bristows team advising Syncona and OSE was led by corporate partner Marek Petecki, supported by Richard Swaine, Of Counsel.
To find out more about our venture capital and corporate expertise, see here.
For more information, please contact:
katherine.farrell@bristows.com | +44 20 7400 8000
Marek Petecki
Author
Richard Swaine
Author